The editorial notes that the study population for this prospective cohort study (PROMISSE) was limited – it only included women who had inactive SLE or mild to moderate SLE activity and had reached >12 weeks of pregnancy, who were on doses of prednisone below 20 mg/day, and who and were free of diabetes, uncontrolled hypertension, heavy proteinuria, microscopic haematuria, and abnormal serum creatinine levels. Nonetheless, they say that the researchers should be congratulated on the advances they have achieved in this difficult clinical area, with their findings confirming the current approaches to managing pregnancy in women with SLE.